Cargando…

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy

Background: Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) combined with chemotherapy in patients with RAS (rat sarcoma viral oncogene homolog) wild-type metastatic colorectal cancer (mCRC) can alleviate and stabilize the disease, effectively prolong the progression-free surviv...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Meiqin, Wang, Zeng, Lv, Wangxia, Pan, Hongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006990/
https://www.ncbi.nlm.nih.gov/pubmed/35433839
http://dx.doi.org/10.3389/fmolb.2022.870395
_version_ 1784686768950345728
author Yuan, Meiqin
Wang, Zeng
Lv, Wangxia
Pan, Hongming
author_facet Yuan, Meiqin
Wang, Zeng
Lv, Wangxia
Pan, Hongming
author_sort Yuan, Meiqin
collection PubMed
description Background: Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) combined with chemotherapy in patients with RAS (rat sarcoma viral oncogene homolog) wild-type metastatic colorectal cancer (mCRC) can alleviate and stabilize the disease, effectively prolong the progression-free survival (PFS) and overall survival (OS), and improve the overall response rate (ORR), which is the first-line treatment standard scheme for RAS wild-type mCRC currently. However, whether anti-EGFR mAb can be used for the maintenance treatment after the first-line treatment of mCRC remains controversial. We reviewed the recent studies on anti-EGFR mAb. The contents include five parts, introduction, anti-EGFR mAb in mCRC and its status in first-line therapy, establishment of the maintenance treatment pattern after the standard first-line treatment for mCRC, research progress of anti-EGFR mAb in mCRC maintenance therapy, and conclusion. More studies support the maintenance treatment of anti-EGFR mAb, but some researchers raise the problems about high cost and drug resistance. Despite lack of the maintenance evidence of anti-EGFR mAb, especially lack of large-scale phase III prospective clinical trials, with the emergence of new evidence and more accurate screening of treatment-dominant groups, maintenance therapy with anti-EGFR mAb monotherapy or anti-EGFR mAb combined with fluorouracil-based schemes after first-line chemotherapy combined with anti-EGFR mAb therapy might strive for more treatment opportunities, optimize treatment strategies and prolong treatment continuity, and finally, lead to more survival benefit for suitable patients.
format Online
Article
Text
id pubmed-9006990
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90069902022-04-14 The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy Yuan, Meiqin Wang, Zeng Lv, Wangxia Pan, Hongming Front Mol Biosci Molecular Biosciences Background: Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) combined with chemotherapy in patients with RAS (rat sarcoma viral oncogene homolog) wild-type metastatic colorectal cancer (mCRC) can alleviate and stabilize the disease, effectively prolong the progression-free survival (PFS) and overall survival (OS), and improve the overall response rate (ORR), which is the first-line treatment standard scheme for RAS wild-type mCRC currently. However, whether anti-EGFR mAb can be used for the maintenance treatment after the first-line treatment of mCRC remains controversial. We reviewed the recent studies on anti-EGFR mAb. The contents include five parts, introduction, anti-EGFR mAb in mCRC and its status in first-line therapy, establishment of the maintenance treatment pattern after the standard first-line treatment for mCRC, research progress of anti-EGFR mAb in mCRC maintenance therapy, and conclusion. More studies support the maintenance treatment of anti-EGFR mAb, but some researchers raise the problems about high cost and drug resistance. Despite lack of the maintenance evidence of anti-EGFR mAb, especially lack of large-scale phase III prospective clinical trials, with the emergence of new evidence and more accurate screening of treatment-dominant groups, maintenance therapy with anti-EGFR mAb monotherapy or anti-EGFR mAb combined with fluorouracil-based schemes after first-line chemotherapy combined with anti-EGFR mAb therapy might strive for more treatment opportunities, optimize treatment strategies and prolong treatment continuity, and finally, lead to more survival benefit for suitable patients. Frontiers Media S.A. 2022-03-30 /pmc/articles/PMC9006990/ /pubmed/35433839 http://dx.doi.org/10.3389/fmolb.2022.870395 Text en Copyright © 2022 Yuan, Wang, Lv and Pan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Yuan, Meiqin
Wang, Zeng
Lv, Wangxia
Pan, Hongming
The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
title The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
title_full The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
title_fullStr The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
title_full_unstemmed The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
title_short The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
title_sort role of anti-egfr monoclonal antibody in mcrc maintenance therapy
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006990/
https://www.ncbi.nlm.nih.gov/pubmed/35433839
http://dx.doi.org/10.3389/fmolb.2022.870395
work_keys_str_mv AT yuanmeiqin theroleofantiegfrmonoclonalantibodyinmcrcmaintenancetherapy
AT wangzeng theroleofantiegfrmonoclonalantibodyinmcrcmaintenancetherapy
AT lvwangxia theroleofantiegfrmonoclonalantibodyinmcrcmaintenancetherapy
AT panhongming theroleofantiegfrmonoclonalantibodyinmcrcmaintenancetherapy
AT yuanmeiqin roleofantiegfrmonoclonalantibodyinmcrcmaintenancetherapy
AT wangzeng roleofantiegfrmonoclonalantibodyinmcrcmaintenancetherapy
AT lvwangxia roleofantiegfrmonoclonalantibodyinmcrcmaintenancetherapy
AT panhongming roleofantiegfrmonoclonalantibodyinmcrcmaintenancetherapy